SLC5A2 and heart failure: We also found a study which reported a 5–8% decrease in LV systolic diameter and LV diastolic diameter in patients with heart failure and a reduced EF (HFrEF) who were treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) [14].